Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 3/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | RAMP3 | O60896 | 10/20 | 0.47 |
| ▸ | CALCR | P30988 | 10/20 | 0.47 |
| ▸ | AKT1 | P31749 | 1/20 | 0.46 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.46 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.44 |
| ▸ | CASP3 | P42574 | 2/20 | 0.44 |
| ▸ | CASP1 | P29466 | 1/20 | 0.44 |
| ▸ | CASP2 | P42575 | 1/20 | 0.44 |
| ▸ | CASP7 | P55210 | 1/20 | 0.44 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15185936 | 0.82 | RAMP3 (0.51) | RAMP3CALCRAKT1 | |
| SCHEMBL29436324 | 0.80 | SLC15A2 (0.57) | FOLH1TDP1PLCG1CAPN1 | |
| SCHEMBL10033418 | 0.78 | TDP1 (0.51) | FOLH1TDP1CAPN1CASP3CASP1 | |
| SCHEMBL31378126 | 0.78 | TDP1 (0.66) | FOLH1TDP1CAPN1 | |
| SCHEMBL31433227 | 0.76 | TDP1 (0.59) | FOLH1TDP1CAPN1CASP3CASP1 | |
| SCHEMBL20827735 | 0.76 | FOLH1 (0.51) | FOLH1TDP1CAPN1CASP3CASP1 | |
| SCHEMBL12303008 | 0.75 | CNR1 (0.54) | FOLH1TDP1CAPN1CASP3CASP1 | |
| SCHEMBL9807479 | 0.75 | TDP1 (0.77) | FOLH1TDP1CAPN1 | |
| SCHEMBL13311812 | 0.75 | TDP1 (0.56) | FOLH1TDP1CAPN1CASP3CASP1 | |
| SCHEMBL13311852 | 0.74 | TDP1 (0.55) | FOLH1TDP1CAPN1CASP3CASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170107248-A1 | SITE SPECIFIC PROTEIN MODIFICATIONS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2017-04-20 | — | — | US | disclosed |
| WO-2015200080-A1 | SITE SPECIFIC PROTEIN MODIFICATIONS | NOVARTIS AG (CH) | 2015-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170107248-A1 | SITE SPECIFIC PROTEIN MODIFICATIONS | PTMS, DNPEP, ANPEP | FOLH1 79/4885TDP1 2957/4885RAMP3 636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.